# Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report

## TL;DR

A patient with relapsing thrombotic thrombocytopenic purpura was successfully treated with caplacizumab and obinutuzumab without plasma exchange.

## Contribution

This case report presents a TPE-free treatment approach for TTP using caplacizumab and obinutuzumab.

## Key findings

- A 55-year-old female with relapsing TTP was treated successfully without therapeutic plasma exchange.
- The treatment included caplacizumab, steroids, and obinutuzumab, showing safety and effectiveness.

## Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening disorder due to a severe acquired or inherited ADAMTS13 deficiency. So far, therapeutic algorithms almost universally include the prompt initiation of therapeutic plasma exchange (TPE). We firstly report a 55-year-old female with a history of relapsing TTP who was managed exclusively with caplacizumab, steroids and the second generation fully humanized anti-CD20 monoclonal antibody obinutuzumab during a relapse without the need of TPE throughout the whole disease course. This case illustrates the safety and effectiveness of a TPE-free TTP management using prompt initiation of caplacizumab and obinutuzumab.